PRMT5 and pancreatic ductal adenocarcinoma: PR5-LL-CM01 demonstrated binding affinity to the active site of PRMT5 in silico, and it displayed anti-tumor effects in both in vitro and in vivo systems of pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) superior to the commercial inhibitor of PRMT5, EPZ01566627.